# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target ...
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...
HC Wainwright & Co. reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price target.
Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target ...
HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.320) per share which beat the analyst consensus estimate o...